Francis Medical Announces First Commercial Procedure with the Vanquish® Water Vapor System for Prostate Tissue Ablation

MINNEAPOLIS, Feb. 3, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately-held medical device company, announced the first commercial procedure using the Vanquish Water Vapor Ablation System at Pinnacle Surgery Center in Austin, Texas, by Dr. Eric Giesler with Urology Austin. The procedure was performed on a patient diagnosed with intermediate risk, localized prostate cancer, like those in the company's VAPOR 2 pivotal study. This first procedure marks a major milestone for the company and the millions of men looking for a minimally invasive alternative to ablate targeted prostate tissue with lower potential risk of the side effects common with traditional therapies.

The Vanquish System is a transurethral, ultrasound and electromagnetically guided, thermal water vapor device used to convectively ablate targeted prostate tissue. The Vanquish System received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in November 2025. This FDA clearance was supported by positive 12-month follow-up data on the first 110 patients enrolled in the company's ongoing VAPOR 2 clinical study. The VAPOR 2 study is a prospective, multicenter, single-arm study of 235 patients with intermediate-risk, localized prostate cancer across 26 U.S. clinical sites. Performed on an outpatient basis, initial procedures were completed in February 2025, and patients will continue to be followed to gather longer-term outcomes to support a premarket approval (PMA) submission for an expanded indication for the management of clinically localized prostate cancer.

"As a VAPOR 2 clinical study site, it is gratifying to see this innovative technology receive FDA clearance," said Dr. Giesler. "This allows me to offer patients an option that is designed to deliver reliable ablation while potentially reducing the risk of side effects. Our first commercial procedure with the Vanquish System underscores Urology Austin's commitment to bringing rigorously evaluated, advanced technologies to our community."

Six-month biopsy data on the first 110 patients in the VAPOR 2 study demonstrated elimination of targeted MRI visible, biopsy confirmed, intermediate risk (≥GGG2) disease in 91% of patients following a single Vanquish procedure. There were no device-related serious adverse events and low rates of urinary incontinence and erectile dysfunction, two common side effects in traditional prostate cancer treatments, such as surgery or radiation. Additionally, the Vanquish System demonstrated the ability to effectively ablate target lesions in all prostate locations, addressing a significant limitation of existing options.

Patient experience and satisfaction results have also been extremely encouraging in the VAPOR 2 study so far. Patients indicated minimal to no pain after the Vanquish procedure and at 12 months post procedure, 93% of patients were extremely satisfied or satisfied, and 94% believed that receiving the treatment was a wise decision.

"Today marks a milestone that took years of innovation, collaboration, and clinical partnerships to achieve," said Dr. Christopher Dixon, Francis Medical chief medical officer. "I am proud of the Vanquish System and the potential this technology has to deliver clinical outcomes without negatively impacting patients' quality of life, as is commonly seen with traditional treatment options."

Disclosure: The Vanquish^® Water Vapor Ablation System has been cleared as a tool for the thermal ablation of targeted prostate tissue via a transurethral approach. The FDA has not evaluated the Vanquish System for the treatment of any disease, including prostate cancer, or evaluated the Vanquish System for any long-term prostate cancer treatment outcomes.

About Francis Medical
Francis Medical is committed to developing urological cancer treatments that are tough on cancer and gentle on patients, driven by a compassionate belief and clinical data supporting that minimally invasive therapies safely and effectively treat cancerous tissue. The inventor, Michael Hoey, founded Francis Medical as a tribute to and legacy of his father, Francis Hoey, who endured prostate cancer treatments that had harsh implications on his everyday life before he died from the disease in 1991. Unfortunately, current prostate cancer treatments, which come with side effects like urinary incontinence and erectile dysfunction, are not much different than what Francis Hoey encountered. In contrast, water vapor technology applies the thermal energy stored in sterile water vapor to ablate targeted prostate tissue via a transurethral procedure, potentially minimizing life-altering side effects. For more information on Francis Medical, visit www.francismedical.com or call (763) 951-0370.

Investor Contacts
Michael Kujak, CEO, Francis Medical
[email protected]
612-910-9790

Brian Johnston, Gilmartin Group
[email protected]

Media Contact
Shelli Lissick, Bellmont Partners
[email protected]
651-276-6922

SOURCE Francis Medical, Inc.